Skip to main content

Table 5 Conductance catheter derived parameters of left ventricular function in animals subjected to acute pulmonary hypertension

From: Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension

Parameter Treatment Baseline Pulmonary hypertension
    Pre-inhalation 5 minutes after inhalation
Mw (mWatt·s/ml) Iloprost 8.29 ± 1.66 10.67 ± 2.45* 8.08 ± 2.22
  Control 7.54 ± 1.06 9.01 ± 1.27* 9.24 ± 2.69
Emax (mmHg/ml) Iloprost 1.10 ± 0.46 1.51 ± 0.74 1.20 ± 0.66
  Control 1.13 ± 0.62 1.29 ± 0.75 1.64 ± 0.95
LVEF (%) Iloprost 61 ± 5 63 ± 12 59 ± 13
  Control 57 ± 9 53 ± 7 50 ± 5
τ/RR (ms) Iloprost 0.06 ± 0.02 0.08 ± 0.02 0.07 ± 0.01
  Control 0.07 ± 0.01 0.07 ± 0.01 0.08 ± 0.02
β (ml-1) Iloprost 0.11 ± 0.03 0.11 ± 0.06 0.04 ± 0.03*
  Control 0.11 ± 0.04 0.13 ± 0.09 0.09 ± 0.05
C (ml/mmHg) Iloprost 0.72 ± 0.23 0.60 ± 0.20 0.64 ± 0.27
  Control 0.88 ± 0.27 0.71 ± 0.25* 0.66 ± 0.21*
Ea (mmHg/ml) Iloprost 1.87 ± 0.51 1.68 ± 0.44 1.67 ± 0.50
  Control 1.80 ± 0.46 1.93 ± 0.55 1.95 ± 0.56
Emax/Ea Iloprost 0.60 ± 0.24 0.92 ± 0.50 0.69 ± 0.30
  Control 0.62 ± 0.24 0.67 ± 0.31 0.86 ± 0.48
  1. Values are shown for baseline and in pulmonary hypertension before inhalation and 5 minutes after inhalation of either iloprost or control. For the complete experimental time course, see Additional file 6. Values are expressed as mean ± standard deviation. *P < 0.05 versus baseline. β, chamber stiffness constant of end-diastolic pressure volume relationship; C, aortic compliance; Ea, effective arterial elastance; Emax, slope of the end-systolic pressure-volume relationship; LVEF, left ventricular ejection fraction; Mw, slope of the preload-recruitable stroke work relationship; τ/RR, time constant of ventricular relaxation, corrected for the RR interval.